Article Text

Download PDFPDF

Management of neonatal jaundice in low- and lower-middle-income countries
  1. Shahryar E Mir1,
  2. Berthe A M van der Geest2,3,
  3. Jasper V Been2,3,4
  1. 1Paediatrics, Dijklander Hospital, Purmerend, The Netherlands
  2. 2Paediatrics, Division of Neonatology, Erasmus MC - Sophia Children’s Hospital, University Medical Centre Rotterdam, Rotterdam, The Netherlands
  3. 3Obstetrics and Gynaecology, Erasmus MC - Sophia Children’s Hospital, University Medical Centre Rotterdam, Rotterdam, The Netherlands
  4. 4Public Health, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands
  1. Correspondence to Dr Jasper V Been; j.been{at}erasmusmc.nl

Statistics from Altmetric.com

More than 85% of newborns develop some degree of jaundice during the first days of life. Often a benign condition, the yellowish discolouration of the skin, sclerae, and mucous membranes in newborn infants is caused by unconjugated hyperbilirubinaemia, which may result from increased production of bilirubin, limited ability to conjugate bilirubin, and/or slow hepatic-enteric clearance of bilirubin.1 A small proportion of newborns develops extreme hyperbilirubinaemia, that is, a total serum bilirubin (TSB) level of 25 mg/dL (428 µmol/L) or more. When it is not timely recognised or treated, extreme unconjugated hyperbilirubinaemia may lead to acute bilirubin encephalopathy. This in turn carries a risk of developing a spectrum of long-term neurological sequelae known as kernicterus spectrum disorders (KSD), encompassing ‘classical kernicterus’ but also milder forms of permanent brain damage caused by bilirubin neurotoxicity.1 2 Worldwide, it is estimated that extreme hyperbilirubinaemia affects at least 481 000 late-preterm and term newborn infants annually, resulting in 114 000 deaths and more than 63 000 survivors with moderate or severe long-term disability.1 3 More than 75% of affected infants live in low-income and lower-middle-income countries. Moreover, in South Asia severe hyperbilirubinaemia is the seventh leading cause of neonatal mortality.1

When timely recognised, clinically significant hyperbilirubinaemia can be treated with conventional phototherapy and in more severe cases exchange transfusion, thus reducing the risk of KSD. Relatively uncommon in high-income countries, exchange transfusions …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.